Clinical Trials Directory

Trials / Conditions / Advanced Triple Negative Breast Cancer

Advanced Triple Negative Breast Cancer

13 registered clinical trials studyying Advanced Triple Negative Breast Cancer — 7 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingStudy of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Can
NCT07367178
MedSIRPhase 2
Not Yet RecruitingTier Palliative Care For Patients With Advanced Heart Failure or Cancer
NCT07391956
Icahn School of Medicine at Mount SinaiN/A
Not Yet RecruitingFirst-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
NCT07299409
Nathalie LevasseurPhase 2
Not Yet RecruitingHIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer
NCT06849492
Fudan UniversityPhase 2
RecruitingPhase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metro
NCT06771609
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2
RecruitingA Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Canc
NCT06685796
BeBetter Med IncPhase 2
UnknownSingle-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer
NCT05686720
First Affiliated Hospital of Shantou University Medical CollegeEARLY_Phase 1
RecruitingApatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
NCT05019690
Fujian Cancer HospitalPhase 1 / Phase 2
TerminatedA Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior The
NCT04927884
ImmunityBio, Inc.Phase 1 / Phase 2
TerminatedA Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced
NCT03861403
Leap Therapeutics, Inc.Phase 1
CompletedVinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
NCT03254654
Fudan UniversityPhase 2
WithdrawnA Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumo
NCT02661100
Case Comprehensive Cancer CenterPhase 1 / Phase 2
WithdrawnA First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
NCT02038699
Jazz PharmaceuticalsPhase 1 / Phase 2